Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 468

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 468
---
|:--|
| Numerator:                                                                        |     |                       |             |   |
| TuHURA Biosciences, Inc. - Net loss attributable to common stockholders           |     | $                     | (36,362,673 | ) |
| Denominator:                                                                      |     |                       |             |   |
| Weighted average shares outstanding - basic and diluted(2)                        |     |                       |  42,284,525 |   |
| Net loss per share:                                                               |     |                       |             |   |
| TuHURA Biosciences, Inc. - Net loss attributable to common stockholders per share |     | $                     |       (0.86 | ) |
| Excluded securities:                                                              |     |                       |             |   |
| TuHURA Warrants(2)                                                                |     |                       |  10,965,630 |   |
| TuHURA Options(2)                                                                 |     |                       |   6,587,057 |   |
| CVR Shares(2)                                                                     |     |                       |   1,539,938 |   |

| (1) | TuHURA Biosciences, Inc. - Net loss attributable to common stockholders per share includes the related pro forma adjustments as referred to within the section “Unaudited Pro Forma Condensed Combined Financial Information.” |

F-198

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

| (2) | The potentially dilutive outstanding securities were excluded from the computation of the TuHURA Biosciences, Inc. - Net loss attributable to common stockholders per share, basic and diluted, because their effect would have been anti-dilutive and/or issuance or vesting of such shares is contingent upon the satisfaction of certain conditions which were not satisfied by the end of the periods presented. |

The following table presents a roll-forward of the shares issued and assumed to be issued following the consummation of the Kintara Merger and the transactions leading up to the closing of the Mergers:

|                                                                       |     | Common Shares Issued or 
 Assumed to be Issued    |            |
| TuHURA Biosciences, Inc. weighted average shares after Kintara Merger |     |                         | 42,284,525 |
| Shares issued as purchase consideration in Mergers                    |     |                         |  3,998,054 |
| Shares issued in connection